A recently published postmarketing study has shown that dabigatran causes a significantly higher risk of extracranial bleeding than VKAs in clinical practice.3 It was also found that NVAF patients ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIALS, Herbert J.A. Rolden, Janneke P.C. Grutters, Gert Jan van der Wilt, Angela H.E.M. Maas